Every patient is different. Thus, they react to drugs in different ways. Precision dosing is a key step toward achieving the goals of precision medicine, a global objective supported by world leaders. The emerging precision dosing field harnesses the explosion of genomic data and various markers of bodily functions using mathematical modeling to ensure that individuals get the best possible treatment.
Attend our webinar to learn how modeling and simulation approaches support the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient.
Ms. Niloufar Marsousi, a pharmacist completing her doctorate in clinical pharmacology at Geneva University Hospitals, will present her research on using a PBPK model to support prospective dose adjustment of ticagrelor in ritonavir-treated HIV patients. Ms. Marsousi will be joined by Dr. Jeannine McCune, a Professor at the University of Washington College of Pharmacy and a Full Member at the Fred Hutchinson Cancer Research Center. Dr. McCune will discuss successful implementation of therapeutic drug monitoring using Bayesian parameter estimation to personalize cyclophosphamide dosing. She will also explain how similar modeling techniques should be applied to busulfan, a medication often dosed using therapeutic drug monitoring.
About Our Speakers
Niloufar Marsousi is a pharmacist completing her PhD in clinical pharmacology in the Clinical Pharmacology and Toxicology department of Geneva University Hospitals in Switzerland. Her research focus includes PBPK modeling in combination with clinical studies in the field of drug-drug interactions (DDI) mostly involving antiplatelet agents such as clopidogrel, prasugrel and ticagrelor and HIV drugs. Her recent project examined the usefulness of PBPK modeling in the assessment of DDI and related dose adjustment, which was published in Clinical Pharmacology and Therapeutics.
Jeannine S. McCune, PharmD, BCOP, is currently a Professor at the University of Washington College of Pharmacy and a Full Member at the Fred Hutchinson Cancer Research Center. Dr. McCune’s research focuses on translational pharmacology of medications used to treat cancer. Her current research is on genetic and non-genetic (eg, age, disease) factors that cause pharmacokinetic variability and how it impacts chemotherapy response. She has published more than 130 abstracts, research articles, and book chapters.
Every patient is different. Thus, they react to drugs in different ways. Precision dosing is a key step toward achieving the goals of precision medicine, a global objective supported by world leaders. The emerging precision dosing field harnesses the explosion of genomic data and various markers of bodily functions using mathematical modeling to ensure that individuals get the best possible treatment.
Watch our webinar to learn how modeling and simulation approaches support the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient.
Dr. Niloufar Marsousi, a pharmacist completing her doctorate in clinical pharmacology at Geneva University Hospitals, presented her research on using a PBPK model to support prospective dose adjustment of ticagrelor in ritonavir-treated HIV patients. Dr. Marsousi was joined by Dr. Jeannine McCune, a Professor at the University of Washington College of Pharmacy and a Full Member at the Fred Hutchinson Cancer Research Center. Dr. McCune explained how modeling techniques can be applied to busulfan, a medication often dosed using therapeutic drug monitoring.